DR. TIMOTHY DAVID GILLIGAN M.D.
Prescription History 1912998113
Internal Medicine - Medical Oncology in Cleveland, OH

NPI Status: Active since November 04, 2005

Contact Information

9500 EUCLID AVE
R35
CLEVELAND, OH
ZIP 44195
Phone: (216) 444-0391
Fax: (216) 636-1711

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. TIMOTHY DAVID GILLIGAN M.D., an active Medical Oncology specialist practicing in Cleveland, OH. Our medical registry currently tracks 10 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 639 documented patient claims. Among these therapy options, the most frequently utilized medication is Abiraterone Acetate, which accounts for 237 claims alone.


Abiraterone Acetate

Generic Formulation: Abiraterone AcetateSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 237
30-Day Fills 237.0
Days Supply 7,066
OH State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills45.7
Peer Average Days Supply1,359
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 438.6% higher than the standard regional baseline profile for OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $480,858.07 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,028.94

State Avg Cost Per Claim

$4,090.39

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER.

Therapeutic Applications

This medication is used to treat prostate cancer. Abiraterone belongs to a class of drugs known as anti-androgens (anti-testosterone). Testosterone, a natural hormone, helps prostate cancer to grow and spread. Abiraterone works by blocking the production of testosterone, thereby slowing the growth and spread of prostate cancer. This medication should not be given to women or children.

Bicalutamide

Generic Formulation: BicalutamideSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 55
30-Day Fills 99.0
Days Supply 2,966
OH State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills48.6
Peer Average Days Supply1,420
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 96.4% higher than the standard regional baseline profile for OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,304.54 across this reporting matrix range.

Provider Avg Cost Per Claim

$41.90

State Avg Cost Per Claim

$47.83

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Bicalutamide is used to treat prostate cancer. This medication works by blocking the action of male hormones in the prostate, slowing the growth of cancer cells. This medication should not be used in women and children.

Erleada

Generic Formulation: ApalutamideSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 25
30-Day Fills 25.0
Days Supply 715
OH State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills37.9
Peer Average Days Supply1,132
Conservative Utilization

This provider writes prescriptions for this formulation 30.6% less frequently than the standard regional baseline metric for practitioners inside OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $293,972.13 across this reporting matrix range.

Provider Avg Cost Per Claim

$11,758.89

State Avg Cost Per Claim

$14,030.28

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apalutamide is used to treat men with prostate cancer. This medication belongs to a class of drugs known as anti-androgens (anti-testosterone). It works by blocking the effects of testosterone to slow the growth and spread of prostate cancer.

Levothyroxine Sodium

Generic Formulation: Levothyroxine SodiumSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 23
30-Day Fills 37.0
Days Supply 1,110
OH State Average Benchmarks
Peer Average Claims165.0
Peer Average 30-Day Fills357.3
Peer Average Days Supply10,451
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 86.1% less volume than the regional standard for practitioners inside OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $430.36 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.71

State Avg Cost Per Claim

$16.97

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.

Therapeutic Applications

Levothyroxine is used to treat an underactive thyroid (hypothyroidism). It replaces or provides more thyroid hormone, which is normally produced by the thyroid gland. Low thyroid hormone levels can occur naturally or when the thyroid gland is injured by radiation/medications or removed by surgery. Having enough thyroid hormone is important for maintaining normal mental and physical activity. In children, having enough thyroid hormone is important for normal mental and physical development. This medication is also used to treat other types of thyroid disorders (such as thyroid cancer). This medication should not be used to treat infertility unless it is caused by low thyroid hormone levels.

Nubeqa

Generic Formulation: DarolutamideSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 465
OH State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills24.3
Peer Average Days Supply725
Conservative Utilization

This provider writes prescriptions for this formulation 33.3% less frequently than the standard regional baseline metric for practitioners inside OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $202,784.76 across this reporting matrix range.

Provider Avg Cost Per Claim

$12,674.05

State Avg Cost Per Claim

$12,438.77

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Darolutamide is used to treat a certain type of prostate cancer. This medication belongs to a class of drugs known as anti-androgens (anti-testosterone). It works by blocking the effects of testosterone to slow the growth and spread of prostate cancer.

Ondansetron Hcl

Generic Formulation: Ondansetron HclSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 180
OH State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills18.7
Peer Average Days Supply144
Conservative Utilization

This provider writes prescriptions for this formulation 38.9% less frequently than the standard regional baseline metric for practitioners inside OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $127.02 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.55

State Avg Cost Per Claim

$14.37

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. It works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Orgovyx

Generic Formulation: RelugolixSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 48
30-Day Fills 48.0
Days Supply 1,418
OH State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills36.8
Peer Average Days Supply1,098
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 33.3% more claims than the standard regional baseline profile for OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $125,069.70 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,605.62

State Avg Cost Per Claim

$2,607.45

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Relugolix is used to treat prostate cancer in men. It is not a cure. Most types of prostate cancer need the male hormone testosterone to grow and spread. Relugolix works by reducing the amount of testosterone that the body makes. This helps slow or stop the growth of cancer cells.

Prednisone

Generic Formulation: PrednisoneSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 142
30-Day Fills 176.0
Days Supply 5,205
OH State Average Benchmarks
Peer Average Claims51.0
Peer Average 30-Day Fills61.0
Peer Average Days Supply1,076
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 178.4% higher than the standard regional baseline profile for OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,072.03 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.55

State Avg Cost Per Claim

$5.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Sunitinib Malate

Generic Formulation: Sunitinib MalateSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 357
OH State Average Benchmarks
Peer Average Claims14.0
Peer Average 30-Day Fills14.8
Peer Average Days Supply398
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $85,616.42 across this reporting matrix range.

Provider Avg Cost Per Claim

$5,036.26

State Avg Cost Per Claim

$7,857.57

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An indole and pyrrole derivative that inhibits VEGFR-2 and PDGFR BETA RECEPTOR TYROSINE KINASES. It is used as an antineoplastic agent for the treatment of GASTROINTESTINAL STROMAL TUMORS, and for treatment of advanced or metastatic RENAL CELL CARCINOMA.

Therapeutic Applications

This medication is used to treat certain types of cancer (kidney, pancreas, and intestinal). It is also used to treat people who are at high risk of the kidney cancer coming back again after having kidney surgery. Sunitinib works by stopping or slowing the growth of cancer tumors. It also works by slowing the growth of new blood vessels within the tumor.

Xtandi

Generic Formulation: EnzalutamideSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 65
30-Day Fills 65.0
Days Supply 1,950
OH State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills36.3
Peer Average Days Supply1,080
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 85.7% higher than the standard regional baseline profile for OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $959,308.41 across this reporting matrix range.

Provider Avg Cost Per Claim

$14,758.59

State Avg Cost Per Claim

$12,796.47

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Enzalutamide is used to treat prostate cancer. This medication belongs to a class of drugs known as anti-androgens (anti-testosterone). It works by blocking the effects of testosterone to slow the growth and spread of prostate cancer.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. TIMOTHY DAVID GILLIGAN M.D. provides transparency into local medical care patterns within Cleveland, OH.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Medical Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.